China Pharma Innovation Hinges On Participation Of Medical Experts – SFDA Drug Registration Director
This article was originally published in PharmAsia News
Executive Summary
China approves less than 10 new chemical entities annually, according to SFDA Director of Drug Registration Wei Zhang, who has urged healthcare professionals to join China’s innovation efforts.
You may also be interested in...
China Drug Approvals Up 26%, Mostly Due To Generics
China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals
China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone
SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)
BrightGene Bets On Remdesivir Amid Patent Questions
Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports